IPO
AVCJ Awards 2021: Operational Value Add: Best & Less Group
Allegro Funds plucked Australian baby and kids retailer Best & Less from its underperforming parent and defied pandemic-related uncertainty to complete a turnaround that culminated in an IPO
AVCJ Awards 2021: Firm of the Year – Large Cap: Baring Private Equity Asia
Baring Private Equity Asia claims that a thematic approach to origination and flexibility on deal structure allow it to pursue opportunities with greater conviction in a high-valuation environment
LionRock launches Hong Kong SPAC
LionRock Capital, an Asian private equity firm that invests in global consumer brands with a China growth angle, is among the first group of sponsors launching special purpose acquisition companies (SPACs) in Hong Kong.
Sinovation's AI solutions business completes $151m HK IPO
AInnovation, a China-based artificial intelligence (AI) solutions provider incubated by Sinovation Ventures, traded down on its Hong Kong debut following a HKD 1.18bn (USD 151m）IPO.
PE-backed Country Style Cooking, Tuhu file for HK listings
Chinese restaurant chain Country Style Cooking (CSC), which was de-listed in the US in 2015, and automotive after-sales service platform Tuhu, which was previously targeting a New York offering, have both filed for IPOs in Hong Kong.
China IPOs: Offshore angst
Private equity exit timelines were thrown into disarray last year when US IPOs abruptly stopped. Regulators have offered some clarity, but investors are unsure when – or if – the magic will return
Ex-CVC Asia head raises $200m SPAC
Generation Asia Acquisition, a special purpose acquisition company (SPAC) sponsored by Roy Kuan, formerly Asia managing partner at CVC Capital Partners, has raised USD 200m through a US offering.
Asia PE investment hits new high in 2021
A rebound in China-based activity took Asia private equity investment to a record USD 105.3bn in the fourth quarter, ensuring that 2021 represents a new high watermark for the industry.
4Q analysis: Record quarter, record year
China rebounds as Asia private equity investment ends 2021 with a bang; bright spots in improving fundraising environment; sponsor-to-sponsor exits thrive while PE-backed IPOs stumble
Novo Tellus targets $111m Singapore SPAC
Novo Tellus Capital Partners, a Southeast Asia-based private equity firm that focuses on middle-market industrial technology opportunities, has filed to list a special purpose acquisition company (SPAC) in Singapore.
Vertex, Tikehau lead Singapore SPAC charge
Special purpose acquisition companies (SPACs) backed by Vertex Venture Holdings (VVH) and Tikehau Capital have filed for listings in Singapore.
China's SenseTime perseveres with IPO despite blacklisting
Chinese artificial intelligence (AI) technology developer SenseTime has relaunched its IPO on the same terms, albeit excluding US investors, after being placed on another blacklist by the US government.
Hong Kong seeks compromise on local SPAC provisions
Hong Kong has compromised on several points of contention in its special purpose acquisition company (SPAC) guidelines, notably removing a requirement that investors can only redeem their shares post-merger if they vote against the deal.
NewQuest set for TPG windfall if Fund V hits $1.75b
The management team of Asia secondaries specialist NewQuest Capital Partners stands to receive a $10 million payout if the firm raises $1.75 billion for its fifth fund, as part of TPG’s acquisition agreement.
Japan's Advantage raises renewables-focused SPAC
Advantage Partners has raised $150 million for a special purpose acquisition company (SPAC) that will target de-carbonization and renewable energy-related assets with a focus on Asia ex-China and Europe.
2022 preview: Japan VC
Japanese VC is growing up fast and looking a little less homogenous in the process. A longstanding growth-stage gap is about to disappear as new actors file in
Q&A: Legend Capital's Richard Li
Richard Li, president of Legend Capital, on evolving US-China relations, the logic behind the recent wave of regulation, investing in line with government policy, and why LPs should get used to onshore exits
2021 in review: Boom time
Cheap debt and a desire for assets that deliver technology-driven growth have propelled Asia private equity investment to new highs and supported a resurgence in exits. But fundraising still fails to convince
Biotech player CANbridge drops on debut after $87m HK IPO
CANbridge Pharmaceuticals, a Beijing-based drug developer that focuses on treatments for cancer and rare diseases, lost 27% in value on its Hong Kong trading debut following a HK$685.1 million ($87.8 million) IPO.
China's SenseTime plans pared back Hong Kong IPO
Chinese artificial intelligence (AI) technology developer SenseTime is looking to raise up to HK$5.99 billion in a Hong Kong IPO that is considerably smaller than originally envisaged.
China's Didi to delist in New York
China ride-hailing platform Didi, which has traded poorly ever since being targeted by regulators in the wake of its IPO in June, plans to delist from the New York Stock Exchange and relist in Hong Kong.
Grab completes SPAC merger, sees volatile trading debut
Southeast Asia ride-hailing platform turned super app Grab experienced a tumultuous first day of trading on NASDAQ following the completion of its merger with a US-listed special purpose acquisition company (SPAC) at an enterprise valuation of $30.4 billion....
PE investors wary of inflation in 2022 - AVCJ Forum
Inflation is top of mind for Asia-focused private equity investors as they assess the various uncertainties facing the industry in 2022, the AVCJ Private Equity & Venture Forum heard.
China biotech IPOs in Hong Kong to stay strong - AVCJ Forum
The frenzy for Chinese biotech developers listing in Hong Kong is expected to continue well into 2022, industry participants told the AVCJ Private Equity & Venture Forum.